Open Access Open Access  Restricted Access Subscription Access

A Review from Code to Cure-Crispr/Cas9 in Modern Therapeutics

Yogita M. Patil, Mrunal D. Pendharkar, Neha P. Patil, Krutadnya P. Patil, Dr. Sunil P. Pawar

Abstract


Clustered frequently interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) gene-editing skill is a promising future tool for giving diseases by efficiently and precisely stopping genes that cause diseases or permanently correcting harmful base mutations. CRISPR-Cas9 represents a ground breaking and highly effective genome editing technology that allows for exact and targeted alterations of DNA sequences within living organisms. Originating from a natural defence mechanism utilized by bacteria, the CRISPR-Cas9 system has gained immense popularity in molecular biology because of its user-friendly nature, programmability, and versatility. The introduction of CRISPR-Cas9 technology signifies a remarkable advancement in gene editing, providing a highly effective, cost-efficient, and programmable method for precise genomic alterations. In contrast to previous genome editing tools like zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), CRISPR-Cas9 is distinguished by its straightforward design and capacity to target nearly any genomic site with high accuracy. This system permits the creation of targeted double-stranded breaks at specified DNA locations, enabling gene knockout, correction of harmful mutations, or the insertion of therapeutic genes through the body's inherent DNA repair mechanisms. Its potential applications are vast, encompassing disease modelling, functional genomics, therapeutic gene modification, and enhancements in agricultural traits. 


Full Text:

PDF

References


Esvelt, K. M., & Wang, H. H. (2013). Genome-scale engineering for systems and synthetic biology. Molecular Systems Biology, 9(1), 641.

El-Mounadi, K., Morales-Floriano, M. L., & Garcia-Ruiz, H. (2020). Principles, applications, and biosafety of plant genome editing using CRISPR–Cas9. Frontiers in Plant Science, 11, 56.

Shino, Y., et al. (1987). Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. Journal of Bacteriology, 169, 5429–5433.

Yang, Y., Xu, J., Ge, S., & Lai, L. (2021). CRISPR/Cas: Advances, limitations, and applications for precision cancer research. Frontiers in Medicine, 8, 649896.

Wu, Y., et al. (2013). Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell, 13, 659–662.

Davidson, A. R., Lu, W. T., Stanley, S. Y., Wang, J., & Sontheimer, E. J. (2020). Anti-CRISPRs: Protein inhibitors of CRISPR–Cas systems. Annual Review of Biochemistry, 89, 309–332.

Menchaca, A., Santos-Neto, P. C. D., & Mulet, A. P. (2020). CRISPR in livestock: From editing to printing. Theriogenology, 150, 247–254.

Mladenov, E., & Iliakis, G. (2011). Induction and repair of DNA double-strand breaks: The increasing spectrum of nonhomologous end joining pathways. Mutation Research, 711(1–2), 61–72.

Redman, M., King, A., Watson, C., & King, D. (2016). What is CRISPR/Cas9? Archives of Disease in Childhood: Education and Practice Edition, 101(4), 213–215.

Cho, S. W., Kim, S., Kim, J. M., & Kim, J. S. (2013). Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nature Biotechnology, 31(3), 230–232.


Refbacks

  • There are currently no refbacks.